When will the patent protection period of fotantinib/fotantinib expire and what is the status of generic drugs?

Fostamatinib is a small molecule oral SYK inhibitor developed by Rigel Pharmaceuticals with the trade name Tavalisse. It has been approved by the FDA for the treatment of patients with chronic immune thrombocytopenia (ITP) who have failed to respond to first-line treatment. Its mechanism is through targeted inhibition of spleen tyrosine kinase (SYK), thereby reducing macrophage-mediated platelet destruction. It is a type of targeted therapeutic drug with a unique immune regulatory mechanism. In recent years, fotantinib has also been actively expanding into the treatment of other autoimmune diseases and rare diseases, including rheumatoid arthritis, IgA nephropathy and other fields, showing broad indication potential.

Regarding intellectual property protection, fotantinib’s chemical composition, synthesis methods, uses, etc. have all obtained patent protection. According to the US Patent Information Platform (USPTO), its core patents will expire around 2032, including key pharmaceutical preparation and delivery method patents. It is worth noting that Rigel has also tried to extend the market exclusivity period of the drug through subsequent patent applications and indication extensions. In addition, Tavalisse has also obtained orphan drug designation in the United States, which allows it to enjoy longer market exclusivity in certain indications, which is conducive to its commercial operations and pricing strategy.

As of now, there are no generic fotantinib drugs approved for marketing in overseas markets. On the one hand, the reason is related to its patent barriers; on the other hand, because it is an orphan drug and its market size is relatively small, generic drug companies still have a wait-and-see attitude towards its business prospects. However, as patents are about to expire and indications are expanded, pharmaceutical companies in strong generic drug countries such as India and China may begin to submit bioequivalence studies or ANDAs (simplified new drug applications) in the future, laying the foundation for the imitation of fotantinib.

Reference materials:https://go.drugbank.com/drugs/DB12010